OKYO Pharma (NASDAQ:OKYO) Earns Buy Rating from HC Wainwright

OKYO Pharma (NASDAQ:OKYO)‘s stock had its “buy” rating reaffirmed by equities researchers at HC Wainwright in a report issued on Monday,Benzinga reports. They currently have a $7.00 price target on the stock.

OKYO Pharma Trading Up 1.3 %

Shares of OKYO stock traded up $0.02 on Monday, hitting $1.14. 24,936 shares of the stock traded hands, compared to its average volume of 251,364. The firm’s 50-day moving average price is $1.08 and its two-hundred day moving average price is $1.07. OKYO Pharma has a twelve month low of $0.81 and a twelve month high of $1.90.

About OKYO Pharma

OKYO Pharma Limited, a clinical-stage biopharmaceutical company, engages in developing therapeutics for patients suffering from inflammatory eye diseases and ocular pain in the United Kingdom. Its lead preclinical product candidate is OK-101, which is in Phase II clinical trials for the treatment of dry eye disease.